TRCT
TELO icon

Tower Research Capital (TRC)’s Telomir Pharmaceuticals TELO Stock Holding History

Tower Research Capital (TRC)’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1K Buy
+7,920
New +$10.3K ﹤0.01% 3993
2025
Q4 		– Sell
-1,251
Closed -$1.74K – 5685
2025
Q3 		$1.74K Sell
1,251
-7,395
-86% -$11.2K ﹤0.01% 4735
2025
Q2 		$10.8K Buy
8,646
+5,929
+218% +$13.7K ﹤0.01% 3934
2025
Q1 		$8.78K Buy
2,717
+362
+15% +$1.58K ﹤0.01% 3852
2024
Q4 		$9.7K Buy
2,355
+857
+57% +$4.04K ﹤0.01% 3883
2024
Q3 		$9.62K Buy
1,498
+550
+58% +$2.68K ﹤0.01% 3852
2024
Q2 		$4.56K Buy
+948
New +$5.92K ﹤0.01% 4767

Other funds holding TELO

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.04B AUM 22.7% 1-Year Est. Return

Tower Research Capital (TRC)'s TELO Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Telomir Pharmaceuticals (TELO) in Q2 2026: 7,920 shares worth $10.1K. The stake represents ﹤0.01% of the portfolio and ranks #3993 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in TELO as recently as Q3 2025.

Tower Research Capital (TRC) first reported a position in TELO in Q2 2024 and has held it in 7 quarters since. The position peaked at $10.8K in Q2 2025. 33 funds tracked by Wall St. Rank hold TELO as of Q2 2026.

  • Tower Research Capital (TRC) held 7,920 shares of Telomir Pharmaceuticals worth $10.1K as of Q2 2026.
  • Telomir Pharmaceuticals was a new Tower Research Capital (TRC) position in Q2 2026.
  • Telomir Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3993 holding.
  • Tower Research Capital (TRC) first reported a position in Telomir Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
  • Tower Research Capital (TRC)'s Telomir Pharmaceuticals position peaked at $10.8K in Q2 2025.
  • 33 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.